Page last updated: 2024-10-30

mesalamine and Congenital Zika Syndrome

mesalamine has been researched along with Congenital Zika Syndrome in 1 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Abrams, RPM1
Yasgar, A1
Teramoto, T1
Lee, MH1
Dorjsuren, D1
Eastman, RT1
Malik, N1
Zakharov, AV1
Li, W1
Bachani, M1
Brimacombe, K1
Steiner, JP1
Hall, MD1
Balasubramanian, A1
Jadhav, A1
Padmanabhan, R1
Simeonov, A1
Nath, A1

Other Studies

1 other study available for mesalamine and Congenital Zika Syndrome

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr

2020